Palantir shares rise 5% premarket as AI-fueled demand powers annual guidance raise
Investing.com -- Novo Nordisk (NYSE:NVO), a global healthcare company, anticipates that the U.S. Food and Drug Administration (FDA) will implement a ban on compounded copies of its drugs Wegovy and Ozempic. The enforcement is scheduled to commence on May 22, as stated by David Moore, the company’s executive vice president of U.S. operations.
Moore shared this information during an analyst call that followed the release of Novo Nordisk’s first-quarter results. He also mentioned that the company will persist in its efforts to combat illicit compounding. The ban is expected to halt any unauthorized production and distribution of these drugs, which are key products in Novo Nordisk’s portfolio.
The company’s U.S. operations head did not provide further details on the potential impacts of the ban. The enforcement is part of the FDA’s ongoing efforts to regulate the pharmaceutical industry and protect consumers from potentially harmful or ineffective drugs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.